

This is the peer reviewed version of the following article:

Impact of tumor size on the difficulty of laparoscopic left lateral sectionectomies / Arizza, G., Russolillo, N., Ferrero, A., Syn, N.L., Cipriani, F., Aghayan, D., Marino, M.V., Memeo, R., Mazzaferro, V., Chiow, A.K.H., Sucandy, I., Ivanecz, A., Vivarelli, M., Di Benedetto, F., Choi, S.-H., Lee, J.H., Park, J.O., Gastaca, M., Fondevila, C., Efanov, M., et al.. - In: JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES. - ISSN 1868-6974. - 30:5(2023), pp. 558-569. [10.1002/jhbp.1279]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

25/06/2026 13:54

(Article begins on next page)



# HHS Public Access

Author manuscript

*J Hepatobiliary Pancreat Sci.* Author manuscript; available in PMC 2024 May 01.

Published in final edited form as:

*J Hepatobiliary Pancreat Sci.* 2023 May ; 30(5): 558–569. doi:10.1002/jhbp.1279.

This paper has not been presented previously Correspondence: Professor Brian K. P. Goh, MBBS, MMed, MSc, FRCSEd Senior Consultant and Professor, Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Level 5, 20 College Road, Academia, Singapore 169856, Tel: +65-63265564, bsgkp@hotmail.com.  
International robotic and laparoscopic liver resection study group investigators

1. Chung-Yip [Chan](#) (Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital)
2. Mikel [Prieto](#) (Hepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Bilbao, Spain)
3. Juul [Meurs](#) (Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium)
4. Celine [De Meyere](#) (Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium) (Department of Surgery, AZ Groeninge Hospital, Kortrijk, Belgium)
5. Felix [Krenzien](#) (Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany)
6. Moritz [Schmelzle](#) (Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany)
7. Kit-Fai [Lee](#) (Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong SAR, China)
8. Kelvin K. [Ng](#) (Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong SAR, China)
9. Diana [Salimgereeva](#) (Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia)
10. Ruslan [Alikhanov](#) (Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia)
11. Lip-Seng [Lee](#) (Hepatopancreatobiliary Unit, Department of Surgery, Changi General Hospital, Singapore)
12. Jae Young [Jang](#) (Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea)
13. Kevin P. [Labadie](#) (Department of Surgery, University of Washington Medical Center, Seattle, USA)
14. Yutaro [Kato](#) (Department of Surgery, Fujita Health University School of Medicine, Aichi, Japan)
15. Masayuki [Kojima](#) (Department of Surgery, Fujita Health University School of Medicine, Aichi, Japan)
16. Asmund Avdem [Fretland](#) (The Intervention Centre and Department of HPB Surgery, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway)
17. Jacob [Ghotbi](#) (The Intervention Centre and Department of HPB Surgery, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway)
18. Fabricio Ferreira [Coelho](#) (Liver Surgery Unit, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil)
19. Jaime Arthur Pirola [Kruger](#) (Liver Surgery Unit, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil)
20. Victor [Lopez-Lopez](#) (Department of General, Visceral and Transplantation Surgery, Clinic and University Hospital Virgen de la Arrixaca, IMIB-ARRIXACA, El Palmar, Murcia, Spain)
21. Paolo [Magistri](#) (HPB Surgery and Transplantation Unit, United Hospital of Ancona, Department of Experimental and Clinical Medicine Polytechnic University of Marche, Ancona, Italy)
22. Bernardo [Dalla Valle](#) (General and Hepatobiliary Surgery, Department of Surgery, Dentistry, Gynecology and Pediatrics University of Verona, GB Rossi Hospital, Verona, Italy)
23. Margarida [Casellas I Robert](#) (Hepatobiliary and Pancreatic Surgery Unit, Department of Surgery, Dr. Josep Trueta Hospital, IdIBGi, Girona, Spain)
24. Kohei [Mishima](#) (Center for Advanced Treatment of Hepatobiliary and Pancreatic Diseases, Ageo Central General Hospital, Saitama, Japan)
25. Roberto Montalti (Department of Clinical Medicine and Surgery, Division of HPB, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy)

## IMPACT OF TUMOR SIZE ON THE DIFFICULTY OF

26. Mariano Giglio (Department of Clinical Medicine and Surgery, Division of HPB, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy)
27. Alessandro Mazzotta Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Université Paris Descartes, Paris, France
28. Boram Lee (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea)
29. Mizelle D'Silva, (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea)
30. Hao-Ping Wang (Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung)
31. Mansour Saleh (Department of Hepatobiliary Surgery, Assistance Publique Hôpitaux de Paris, Centre Hepato-Biliaire, Paul-Brousse Hospital, Villejuif, France)
32. Franco Pascual (Department of Hepatobiliary Surgery, Assistance Publique Hôpitaux de Paris, Centre Hepato-Biliaire, Paul-Brousse Hospital, Villejuif, France)
33. Amal Suhool (Department of Surgery, Fondazione Poliambulanza, Brescia, Italy)
34. Phan Phuoc Nghia (Department of Surgery, University Medical Center, Ho Chi Minh City, Vietnam)
35. Chetana Lim, (Department of Digestive, HBP and Liver Transplantation, Hôpital Pitie-Salpetrière, Sorbonne Université, Paris, France)
36. Qiu Liu (Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China)
37. Prashant Kadam (Department of Hepatopancreatobiliary and Liver Transplant Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom)
38. Bernardo Dalla Valle (General and Hepatobiliary Surgery, Department of Surgery, Dentistry, Gynecology and Pediatrics University of Verona, GB Rossi Hospital, Verona, Italy)
39. Eric C. Lai (Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China)
40. Maria Conticchio (Unit of Hepato-Pancreat-Biliary Surgery, "F. Miulli" General Regional Hospital, Acquaviva delle Fonti, Bari, Italy)
41. Ugo Giustizieri (HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy)
42. Davide Citterio (HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy)
43. Zewei Chen Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
44. Shian Yu Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
45. Francesco Ardito (Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of the Sacred Heart, Rome, Italy)
46. Simone Vani (Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of the Sacred Heart, Rome, Italy)
47. Epameinondas Dogeas (Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA)
48. Tiing Foon Siow (Division of General Surgery, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan)
49. Federico Mocchegiani (HPB Surgery and Transplantation Unit, United Hospital of Ancona, Department of Experimental and Clinical Medicine Polytechnic University of Marche, Ancona, Italy)
50. Giuseppe Maria Ettore (Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Italy)
51. Marco Colasanti (Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Italy)
52. Yoelimar Guzmán (General & Digestive Surgery, Hospital Clínic, Barcelona, Spain)

# LAPAROSCOPIC LEFT LATERAL SECTIONECTOMIES

*A full list of authors and affiliations appears at the end of the article.*

## Abstract

**Introduction:** Tumor size(TS) represents a critical parameter in the risk assessment of laparoscopic liver resections(LLR). Moreover, TS has been rarely related to the extent of liver resection. The aim of this study was to study the relationship between tumor size and difficulty of laparoscopic left lateral sectionectomy(L-LLS).

**Methods:** The impact of TS cutoffs was investigated by stratifying tumor size at each 10mm-interval. The optimal cut-offs were chosen taking into consideration the number of endpoints which show a statistically significant split around the cut-points of interest and the magnitude of relative risk after correction for multiple risk factors.

**Results:** 1910 L-LLS were included. Overall, open conversion and intraoperative blood transfusion were 3.1% and 3.3%, respectively. The major morbidity rate was 2.7% and 90-days mortality 0.6%. Three optimal TS cut-offs were identified: 40-mm, 70-mm, and 100-mm. All the selected cut-offs showed a significant discriminative power for the prediction of open conversion, operative time, blood transfusion and need of Pringle manoeuvre. Moreover, 70-mm and 100-mm cut-offs were both discriminative for estimated blood loss and major complications. A stepwise increase in rates of open conversion rate ( $Z=3.90, p<0.001$ ), operative time ( $Z=3.84, p<0.001$ ), blood loss ( $Z=6.50, p<0.001$ ), intraoperative blood transfusion rate ( $Z=5.15, p<0.001$ ), Pringle manoeuvre use ( $Z=6.48, p<0.001$ ), major morbidity( $Z=2.17, p=0.030$ ) and 30-days readmission ( $Z=1.99, p=0.047$ ) was registered as the size increased.

**Conclusions:** L-LLS for tumours of increasing size was associated with poorer intraoperative and early postoperative outcomes suggesting increasing difficulty of the procedure. We determined 3 optimal TS cutoffs(40-mm, 70-mm and 100-mm) to accurately stratify surgical difficulty after L-LLS.

## Keywords

laparoscopic liver; laparoscopic hepatectomy; difficulty; size; left lateral sectionectomy

## Introduction

Laparoscopic liver resection (LLR) is now well-accepted globally as a safe and effective surgical procedure. Nonetheless, its implementation in clinical practice is associated with a learning curve and requires a stepwise approach when selecting of cases of increasing complexity. During the Second International Consensus Conference on LLRs held in Morioka in 2014, the panel of experts recommended the use of difficulty scoring systems (DSS) to stratify the technical complexity and risks of LLR, in order to guide surgeons on selecting the appropriate procedure according to their level of experience [1]. Several DSSs have been developed and these are based on parameters such as lesion type, size, location, liver function, extent of liver resection and liver morphology [2–5]. Tumour size

is presently well-recognized as having an important impact on the difficulty of LLR and it has been incorporated into most DSSs [2,3,6]. Larger tumours hinder liver mobilization, alter intraparenchymal vascular topographic anatomy and may require wider parenchymal transections and/or extensive vascular dissections. Their manipulation carries an inherent risk of vascular injury or tumour rupture, resulting in major bleeding and tumour seeding [7].

To date, an optimal tumour size cut-off to stratify the complexity of LLR has not been well-established. The Iwate score uses a single cut-off of 30 mm [2], while the Southampton score [3] categorize tumor size according to two thresholds: 30 and 50 mm; respectively. More recently, Kabir et al [4] proposed 30 mm and 70 mm as ideal thresholds for the stratification of the difficulty of LLR. An important limitation of these studies was that the impact of tumor size had not been correlated with the extent of LLR. Intuitively for example, one would expect that a tumor size >3 cm would have a greater impact on the complexity of LLR in the case of a monosegmentectomy but to a lesser extent in the case of a left lateral sectionectomy or right hepatectomy [8].

Hence, we performed the present study with the aim of investigating the impact of tumor size on the surgical complexity of a single specific LLR procedure, i.e laparoscopic left lateral sectionectomy (L-LLSs). L-LLS is presently one of the most common and usually one of the earliest types of LLR that a surgeon attempts during his/her learning curve [79]. L-LLS is widely regarded as a relatively straightforward LLR, thanks to a wide operative field, an easy liver mobilization, and a relatively thin straight parenchymal transection plane. Hence, DSSs specifically tailored to LLS is of particular importance. The primary objective of this study was to examine the relationship between tumor size and difficulty of L-LLS, and to elucidate the optimal tumor size cut-off for this procedure.

## Methods

This was a post hoc review of 17680 patients who underwent pure LLR at 50 international centers between 2004–2020. Of these, there were 2698 pure LLS performed. After excluding patients who underwent concomitant major surgical procedures (such as colectomies/gastrectomies/ hilar lymphadenectomies/ bile duct resections), repeat liver resections, multiple liver resections, cysts/ cystic tumors or abscesses; study population included 1913 patients. Tumor size for three patients was not recorded. Finally, 1910 patients were included in this analysis.

All institutions obtained their respective approvals according to their local center's requirements. This study was approved by the Singapore General Hospital Institution Review Board (CIRB 2020/2802) and the need for patient consent was waived. The anonymized data were collected in the individual centers. These were collated and analyzed centrally at the Singapore General Hospital.

## Definitions

Liver resections were defined according to the 2000 Brisbane classification [10]. Left lateral sectionectomies were defined as resections of Segment 2 and 3. Tumor size was measured

based on the longest diameter of the tumor on formalin-fixed specimens. Diameter of the largest lesion was used in cases of multiple tumors. Resection difficulty was graded according to the Iwate criteria [2]. Post-operative complications were classified according to the Clavien-Dindo classification and recorded for up to 30 days or during the same hospitalization [11].

### Statistical analyses

The impact of tumor size cutoffs in intervals of 10mm was systematically investigated by iteratively dichotomizing the tumor size at each 10mm-interval and computing treatment effect sizes local to that cutoff. This was accomplished using a user-written Stata implementation of the 'Cutoff\_Finder' R package, with minor modifications to allow the use of Poisson models and quantile regression for computing adjusted relative risks and median differences. To handle baseline imbalances, effect sizes were conditioned on inverse probability-weights, which were estimated from a logistic regression incorporating the following as covariates: age, gender, year of surgery, ASA status, previous abdominal surgery, concomitant minor surgery, cirrhosis, multifocality, difficult posterosuperior segment, malignant pathology, and all components of the Iwate score excluding tumor size. Optimal tumor size cutoffs were then selected by taking into consideration the number of endpoints which show a statistically significant split around the cutoff points of interest, as well as the magnitude of the test statistic (z-score and t-score from modified Poisson and quantile regressions). As a sensitivity analysis, we also estimated empirical cutpoints obtained from maximizing the Youden index in receiver operating characteristics (ROC) analyses of open conversion and use of Pringle's maneuver.

Within tumor size categories, continuous and categorical variables were summarized as medians (IQR) and proportions respectively. Tests of inequality across tumor size categories were performed using Kruskal-Wallis tests and Fisher's exact tests respectively for continuous and categorical baseline and surgical characteristics. Finally, we assessed for the presence and strength of monotonic rank ordering using the Jonckheere-Terpstra and Cochran-Armitage trend tests for continuous and binary dependent variables respectively, with the tumor size category regarded as an ordinal independent variable.

## Results

### Baseline characteristics and perioperative outcomes

The baseline characteristics are summarized in Table 1. The median patient age was 61 years (IQR, 50–71), with a male:female ratio of 1124:786. Cirrhosis was diagnosed in 31.5% of patients and it was complicated by portal hypertension in 7.5% of cases. Malignant lesions were diagnosed in 79.8% of cases with a median tumour size of 35 mm (IQR, 23–58). The median Iwate difficulty score was 5 [IQR, 4–5] corresponding to an intermediate difficulty grade in 92.3% of cases. The median operative time was 160 min (IQR, 112–215) with a median blood loss of 100 cc (IQR, 50–200); open conversion and intraoperative blood transfusion were required in 3.1% and 3.3% of cases, respectively. Pringle manoeuvre was used in 19.5% of cases. The major morbidity rate, defined by a Clavien-Dindo severity score >2, was 2.7%, while 90-day mortality was 0.6%.

### Optimal tumor size cut-offs analysis

Relative risk (RR) for each outcome after correction for age, gender, year of surgery, ASA status, previous abdominal surgery, concomitant minor surgery, cirrhosis, multifocality, malignant pathology, and all components of the Iwate score excluding tumour size, was shown in Table 2.

Taking into consideration the number of endpoints which show a statistically significant split around the cut-points of interest and the magnitude of RR, three optimal cut-offs were identified: 40 mm, 70 mm, and 100 mm (Table 1). All the selected cut-offs showed a significant discriminative power for the prediction of open conversion, operative time, blood transfusion and need of Pringle manoeuvre. Moreover, 70 mm and 100 mm cut-offs were both discriminative also for estimated blood loss and major complications (Figure 1, Table 2).

The cut-off of 30 mm was excluded in favour of 40 mm because in equal of number of predictive variables, the significance for blood transfusion was very “weak” (lower bound of the 95% CI 1.06). ROC analyses (Supplementary Figure S1) confirmed that the 40 mm cut-off was able to maximize the Youden index. The 100 mm cut-off was selected instead of 90 mm because associated to notably larger effect sizes, even if discriminated the same perioperative outcomes. Finally, 60 mm (vs 70 mm) and 110 mm (vs 100 mm) were excluded because associated with lower number of predicted outcomes.

According to the selected cut-offs, four study groups were identified: small 39mm (n=1027), intermediate 40–69mm (n=528), large 70–99mm (n=212) and very large 100 (n=143) lesions. The 4-level classification system thus established was able to increase the AUC for both open conversion (from 0.59 to 0.62) and application of pringle manoeuvre (from 0.59 to 0.61) compared to 40 mm cut-off alone (Supplementary Figure S1).

### Comparison of perioperative characteristics stratified by tumour size (Table 1, 3)

Comparison of preoperative characteristics of patients who underwent L-LLS stratified by tumour size showed that patients with very large lesions (> 100 mm) were younger (median age 54 years) with benign lesions in slightly less than 50% of cases. The diagnosis of cirrhosis and portal hypertension were less common (55.2% and 16.1%, respectively) compared to others cut-off groups.

The comparison of intraoperative outcomes between the groups showed a stepwise increase in rates of open conversion rate ( $Z=3.90$ ,  $p<0.001$ ), operative time ( $Z=3.84$ ,  $p<0.001$ ), blood loss ( $Z=6.50$ ,  $p<0.001$ ), intraoperative blood transfusion rate ( $Z=5.15$ ,  $p<0.001$ ) and Pringle manoeuvre use ( $Z=6.48$ ,  $p<0.001$ ) as the tumor size category increased.

A significant worsening trend was noted for Clavien-Dindo score  $>2$  ( $Z=2.17$ ,  $p=0.030$ ) and 30-days readmission ( $Z=1.99$ ,  $p=0.047$ ) increasing the tumor size categories. Thirty and 90-days mortality rates did not significantly change among the study groups.

## Discussion

Since the early experience of LLR, tumour size has been well-recognized as a critical parameter in the assessment of the difficulty of LLR. In the Louisville Statement, it was suggested that LLR should be restricted to lesions < 50 mm. [12]. However, with the accumulation of clinical evidence on the feasibility and safety of the laparoscopic approach for resection of larger tumours, this has culminated in the recent Southampton Guidelines which excluded tumour size as an independent exclusion criterion for LLR [13]. Recent studies have also confirmed the feasibility and safety of LLR for huge (> 10 cm) tumors [7, 14].

Today, L-LLS is one of the most frequently performed types of LLR and it has been proposed to be the standard of care for lesions located in the left lateral section [12,13,15–17]. This is due to the favourable anatomical morphology and topography of the left lateral section [18]. Nonetheless, unexpected difficulties may still be encountered during L-LLS and a small proportion of cases may undergo an unplanned open conversion even in expert centers [18]. Not unexpectedly, tumour size has also been shown to be an important predictor of open conversion during L-LLS [18].

We performed this study with the primary objective of examining the relationship between tumor size and difficulty of L-LLS, and to elucidate the optimal tumor size cut-off for stratifying the difficulty of this procedure. Presently, commonly used DSS such as the Iwate Criteria [2] and Southampton score [3] have incorporated tumour size in the calculation of the difficulty score. A size cut-off of 3 cm was used for the Iwate criteria whereas the Southampton score utilized a cut-off of 3 and 5 cm. More recently, Ivanecz et al proposed a tumor size cut-off of 38 mm based on a small series of 142 LLR [19]. Subsequently, Kabir et al performed a robust statistical analysis based on 461 LLR and determined that the optimal size cut-off was 3 and 7 cm [4]. A major limitation of these studies was that the proposed size cut-offs was not tailored to the extent of the LLR performed. Moreover, many of the cut-off values were arbitrarily chosen and not based on robust statistical analysis.

To the best of our knowledge, this is the largest study to date to analyse the correlation between tumour size and the outcomes for a specific type of LLR. In the present study, we identified three cutoffs (40 mm, 70 mm and 100 mm) which consistently discriminated major intraoperative outcomes (open conversion rate, operative time, blood loss and transfusion, Pringle maneuver use) as well as postoperative major complications after L-LLS. These findings suggest that increasing tumor size correlated with higher difficulty of L-LLS. Notably, increased frequency of the use of the Pringle Maneuver may not necessarily be a detrimental outcome but may be a surrogate of surgical difficulty.

Previously, Yang et al. tested a tumor size cutoff of 50 mm specifically in a small series of 103 L-LLS, but found no significant discriminative value for perioperative complications, apart from intraoperative blood loss [20]. An important clinical application of our current findings is that it would help guide surgeons embarking on LLR in selecting L-LLS procedures appropriate to their level of experience based on tumor size. Furthermore, these findings should be taken into account when formulating new DSSs in future to enable

more accurate discrimination of the complexity of L-LLS and better comparison between outcomes of LLR during surgical audits.

The main limitation of this study is due to its retrospective nature although many centers had a prospective database. Furthermore, as an international multicenter study, there would be heterogeneity in the surgical technique and perioperative management of L-LLS between the different centers. It is also important to note that tumor size in this study was measured based on postoperative pathological specimens which may vary from measurements made based on preoperative imaging. Nonetheless, its main strength was the large number of patients analysed from an international database which allowed robust statistical analysis and providing a wide generalizable experience reflective of contemporary real-world practice.

## Conclusions

In this study, we found that L-LLS for tumours of increasing size was associated with poorer intraoperative and early postoperative outcomes suggesting increasing difficulty of the procedure. We determined 3 optimal tumour size cutoffs (40 mm, 70 mm and 100 mm) which accurately stratified the surgical difficulty of L-LLS.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Authors

Giada Arizza, MD<sup>1</sup>, Nadia Russolillo, MD<sup>1</sup>, Alessandro Ferrero, MD<sup>1</sup>, Nicholas L. Syn, MBBS<sup>2</sup>, Federica Cipriani, MD, PhD<sup>3</sup>, Davit Aghayan, MD, PhD<sup>4</sup>, Marco V. Marino, MD, PhD, FACS, FEBS<sup>5</sup>, Riccardo Memeo, MD<sup>6</sup>, Vincenzo Mazzaferro, MD, PhD<sup>7</sup>, Adrian K. H. Chiow, MBBS, MMed, FRCS<sup>8</sup>, Iswanto Sucandy, MD, FACS<sup>9</sup>, Arpad Ivanecz, MD, PhD<sup>10</sup>, Marco Vivarelli, MD<sup>11</sup>, Fabrizio Di Benedetto, MD, PhD, FACS<sup>12</sup>, Sung-Hoon Choi, MD<sup>13</sup>, Jae Hoon Lee, MD, PhD<sup>14</sup>, James O. Park., MD<sup>15</sup>, Mikel Gastaca, MD<sup>16</sup>, Constantino Fondevila, MD<sup>17</sup>, Mikhail Efanov, MD, PhD<sup>18</sup>, Fernando Rotellar, MD, PhD<sup>19</sup>, Gi-Hong Choi, MD<sup>20</sup>, Ricardo Robles-Campos, MD<sup>21</sup>, Xiaoying Wang., MD, PhD<sup>22</sup>, Robert P. Sutcliffe, MD, FRCS<sup>23</sup>, Johann Pratschke, MD<sup>24</sup>, Chung Ngai Tang, MBBS, FRCS<sup>25</sup>, Charing C. Chong, MBBS, FRCS<sup>26</sup>, Mathieu D'Hondt, MD, PhD<sup>27</sup>, Chee Chien Yong, MD<sup>28</sup>, Andrea Ruzzenente, MD<sup>29</sup>, Paolo Herman, MD, PhD<sup>30</sup>, T. Peter Kingham, MD<sup>31</sup>, Olivier Scatton, MD, PhD<sup>32</sup>, Rong Liu, MD, PhD<sup>33</sup>, Giovanni Battista Levi Sandri, MD, PhD<sup>34</sup>, Olivier Soubrane, MD<sup>35</sup>, Alejandro Mejia, MD<sup>36</sup>, Santiago Lopez-Ben, MD<sup>37</sup>, Kazateru Monden, MD, PhD<sup>38</sup>, Go Wakabayashi, MD, PhD<sup>39</sup>, Daniel Cherqui, MD<sup>40</sup>, Roberto I. Troisi, MSc, MD, PhD, FEBS<sup>41</sup>, Mengqiu Yin, MD<sup>42</sup>, Felice Giuliani, MD<sup>43</sup>, David Geller, MD<sup>44</sup>, Atsushi Sugioka, MD<sup>45</sup>, Bjorn Edwin, MD, PhD<sup>4</sup>, Tan-To Cheung, MS, MD, FRCS<sup>46</sup>, Tran Cong Duy Long, MD, PhD<sup>47</sup>, Mohammad Abu Hilal, MD, PhD<sup>48</sup>, David Fuks., MD, PhD<sup>35</sup>, Kuo-Hsin Chen., MD<sup>49</sup>,

Luca Aldrighetti, MD, PhD<sup>3</sup>, Ho-Seong Han, MD, PhD<sup>50</sup>, Brian K. P. Goh, MBBS, MMed, FRCS<sup>51,52</sup>,  
International robotic and laparoscopic liver resection study group investigators

## Affiliations

- <sup>1</sup>Department of General and Oncological Surgery. Mauriziano Hospital, Turin, Italy
- <sup>2</sup>Ministry of Health Holdings Singapore and Yong Loo Lin School of Medicine, National University of Singapore, Singapore
- <sup>3</sup>Hepatobiliary Surgery Division, IRCCS San Raffaele Hospital, Milan, Italy
- <sup>4</sup>The Intervention Centre and Department of HPB Surgery, Oslo University Hospital, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- <sup>5</sup>General Surgery Department, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy and Oncologic Surgery Department, P. Giaccone University Hospital, Palermo, Italy
- <sup>6</sup>Unit of Hepato-Pancreatc-Biliary Surgery, "F. Miulli" General Regional Hospital, Acquaviva delle Fonti, Bari, Italy
- <sup>7</sup>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy
- <sup>8</sup>Hepatopancreatobiliary Unit, Department of Surgery, Changi General Hospital, Singapore
- <sup>9</sup>AdventHealth Tampa, Digestive Health Institute, Tampa, Florida, USA
- <sup>10</sup>Department of Abdominal and General Surgery, University Medical Center Maribor, Maribor, Slovenia
- <sup>11</sup>HPB Surgery and Transplantation Unit, United Hospital of Ancona, Department of Sperimental and Clinical Medicine Polytechnic University of Marche. Ancona, Italy
- <sup>12</sup>Hepatopancreatobiliary Surgery and Liver Transplant Unit, University of Modena and Reggio Emilia, Modena, Italy
- <sup>13</sup>Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
- <sup>14</sup>Department of Surgery, Division of Hepato-Biliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- <sup>15</sup>Department of Surgery, University of Washington Medical Center. Seattle, USA
- <sup>16</sup>Hepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
- <sup>17</sup>General and Digestive Surgery, Hospital Clinic, IDIBAPS, CIBERehd, University of Barcelona, Barcelona, Spain

- <sup>18</sup>Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia
- <sup>19</sup>HPB and Liver Transplant Unit, Department of General Surgery, Clinica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain & Institute of Health Research of Navarra (IdisNA), Pamplona, Spain
- <sup>20</sup>Division of Hepatopancreatobiliary Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- <sup>21</sup>Department of General, Visceral and Transplantation Surgery, Clinic and University Hospital Virgen de la Arrixaca, IMIB-ARRIXACA, El Palmar, Murcia, Spain
- <sup>22</sup>Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China
- <sup>23</sup>Department of Hepatopancreatobiliary and Liver Transplant Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
- <sup>24</sup>Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité- Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany
- <sup>25</sup>Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China
- <sup>26</sup>Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong SAR, China
- <sup>27</sup>Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium
- <sup>28</sup>Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung.
- <sup>29</sup>General and Hepatobiliary Surgery, Department of Surgery, Dentistry, Gynecology and Pediatrics University of Verona, GB Rossi Hospital, Verona, Italy
- <sup>30</sup>Liver Surgery Unit, Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
- <sup>31</sup>Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
- <sup>32</sup>Department of Digestive, HBP and Liver Transplantation, Hopital Pitie-Salpetriere, Sorbonne Universite, Paris, France
- <sup>33</sup>Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China
- <sup>34</sup>Division of General Surgery and Liver Transplantation, S. Camillo Hospital, Rome, Italy
- <sup>35</sup>Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Universite Paris Descartes, Paris, France

- <sup>36</sup>The Liver Institute, Methodist Dallas Medical Center, Dallas, Texas, USA
- <sup>37</sup>Hepatobiliary and Pancreatic Surgery Unit, Department of Surgery, Dr. Josep Trueta Hospital, IdIBGi, Girona, Spain
- <sup>38</sup>Department of Surgery, Fukuyama City Hospital, Hiroshima, Japan
- <sup>39</sup>Center for Advanced Treatment of Hepatobiliary and Pancreatic Diseases, Ageo Central General Hospital, Saitama, Japan
- <sup>40</sup>Department of Hepatobiliary Surgery, Assistance Publique Hopitaux de Paris, Centre Hepato- Biliaire, Paul-Brousse Hospital, Villejuif, France
- <sup>41</sup>Department of Clinical Medicine and Surgery, Division of HPB, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy
- <sup>42</sup>Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China
- <sup>43</sup>Hepatobiliary Surgery Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Catholic University of the Sacred Heart, Rome, Italy
- <sup>44</sup>Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
- <sup>45</sup>Department of Surgery, Fujita Health University School of Medicine, Aichi, Japan
- <sup>46</sup>Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
- <sup>47</sup>Department of Hepatopancreatobiliary Surgery, University Medical Center, University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam
- <sup>48</sup>Department of Surgery, University Hospital Southampton, United Kingdom and Department of Surgery, Fondazione Poliambulanza, Brescia, Italy
- <sup>49</sup>Division of General Surgery, Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan
- <sup>50</sup>Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea
- <sup>51</sup>Department of Hepatopancreatobiliary and Transplant Surgery, Division of Surgery, Singapore General Hospital and Division of Surgical Oncology, National Cancer Center Singapore
- <sup>52</sup>Duke National University of Singapore Medical School, Singapore

## Funding

Dr T. P. Kingham was partially supported by the US National Cancer Institute MSKCC Core Grant number P30 CA008748 for this study

## Conflicts of interest


- i. Dr Goh BK has received travel grants and honorarium from Johnson and Johnson, Olympus and Transmedic the local distributor for the Da Vinci Robot.

- ii. Dr Marino MV is a consultant for CAVA robotics LLC.
- iii. Johann Pratschke reports a research grant from Intuitive Surgical Deutschland GmbH and personal fees or non-financial support from Johnson & Johnson, Medtronic, AFS Medical, Astellas, CHG Meridian, Chiesi, Falk Foundation, La Fource Group, Merck, Neovii, NOGGO, pharma- consult Peterson, and Promediceis.
- iv. Moritz Schmelzle reports personal fees or other support outside of the submitted work from Merck, Bayer, ERBE, Amgen, Johnson & Johnson, Takeda, Olympus, Medtronic, Intuitive.
- v. Asmund Fretland reports receiving speaker fees from Bayer.
- vi. Fernando Rotellar reports speaker fees and support outside the submitted work from Integra, Medtronic, Olympus, Corza, Sirtex and Johnson & Johnson.

## References

- [1]. Wakabayashi G, Cherqui D, Geller DA et al. ; Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. *Ann Surg.* 2015 Apr;261(4):619–29. [PubMed: 25742461]
- [2]. Wakabayashi G What has changed after the Morioka consensus conference 2014 on laparoscopic liver resection? *Hepatobiliary Surg Nutr.* Aug 2016;5(4):281–289. [PubMed: 27500140]
- [3]. Halls MC, Berardi G, Cipriani F et al. ; Development and validation of a difficulty score to pre- dict intraoperative complications during laparoscopic liver resection. *Br J Surg.* 2018 Aug;105(9):1182–1191. [PubMed: 29737513]
- [4]. Kabir T, Syn N, Koh YX, Teo JY, Chung AY, Chan CY, Goh BKP. Impact of tumor size on the difficulty of minimally invasive liver resection. *Eur J Surg Oncol.* 2022 Jan;48(1):169–176. [PubMed: 34420824]
- [5]. Russolillo N, Casella M, Langella S, Lo Tesoriere R, Ossola P, Ferrero A. Correlation between anthropometric data and preparatory maneuvers difficulties during laparoscopic right liver resections: a single center prospective study. *Surg Endosc.* 2022 Feb 24.
- [6]. Goh BK, Prieto M, Syn N, et al. Validation and comparison of the Iwate, IMM, Southampton and Hasegawa difficulty scoring systems for primary laparoscopic hepatectomies. *HPB* 2021;23:770–76. [PubMed: 33023824]
- [7]. Cheung TT, Wang X, Efanov M et al. ; International Robotic and Laparoscopic Liver Resection Study Group Collaborators. Minimally invasive liver resection for huge ( 10 cm) tumors: an interna-tional multicenter matched cohort study with regression discontinuity analyses. *Hepatobiliary Surg Nutr.* 2021 Oct;10(5):587–597. [PubMed: 34760963]
- [8]. Goh BK, Kabir T, Syn N. RE: New simple three-level liver resection classification without compromising the performance to predict surgical and postoperative outcomes. *Eur J Surg Oncol* 2022;46:303–4.
- [9]. Hasegawa Y, Nitta H, Sasaki A, Takahara T, Ito N, Fujita T, Kanno S, Nishizuka S, Waka-bayashi G. Laparoscopic left lateral sectionectomy as a training procedure for surgeons learning lap-aoscopic hepatectomy. *J Hepatobiliary Pancreat Sci.* 2013 Jun;20(5):525–30. [PubMed: 23430054]
- [10]. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. *J Hepatobiliary Pancreat Surg.* 2005;12(5):351–5. [PubMed: 16258801]
- [11]. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg.* 2004 Aug;240(2):205–13 [PubMed: 15273542]
- [12]. Buell JF, Cherqui D, Geller DA et al. ; World Consensus Conference on Laparoscopic Surgery. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. *Ann Surg.* 2009 Nov;250(5):825–30. [PubMed: 19916210]
- [13]. Abu Hilal M, Aldrighetti L, Dagher I et al. : The Southampton Consensus Guidelines for Laparoscopic Liver Surgery: From Indication to Implementation. *Ann Surg.* 2018 Jul;268(1):11–18. [PubMed: 29064908]

- [14]. Kabir T, Syn NL, Guo Y, Lim KI, Goh BKP. Laparoscopic liver resection for huge ( > 10 cm) hepatocellular carcinoma: A coarsened exact-matched single-surgeon study. *Surg Oncol.* 2021 Jun;37:101569. [PubMed: 33839442]
- [15]. Goh BKP, Lee SY, Koh YX, Kam JH, Chan CY. Minimally invasive major hepatectomies: a Southeast Asian single institution contemporary experience with its first 120 consecutive cases. *ANZ J Surg.* 2020 Apr;90(4):553–557. [PubMed: 31721400]
- [16]. Goh BKP, Lee SY, Teo JY et al. ; Changing trends and outcomes associated with the adoption of minimally invasive hepatectomy: a contemporary single- institution experience with 400 consecutive resections. *Surg Endosc.* 2018 Nov;32(11):4658–4665. [PubMed: 29967997]
- [17]. Kawaguchi Y, Hasegawa K, Wakabayashi G et al. ; Survey results on daily practice in open and laparoscopic liver resections from 27 centers participating in the second International Consensus Con-ference. *J Hepatobiliary Pancreat Sci.* 2016 May;23(5):283–8. [PubMed: 26946065]
- [18]. Wang HP, Yong CC, Wu AG, et al. Factors associated with an impact of open conversion on the outcomes of minimally- invasive left lateral sectionectomies: an international multicenter study. *Surgery* 2022 in press
- [19]. Ivanecz A, Plahuta I, Magdalenic T, et al. Evaluation of the Iwate model for predicting the difficulty of laparoscopic liver resection: does tumor size matter? *J Gastrointest Surg* 2021;25:1451–60. [PubMed: 32495139]
- [20]. Yang TH, Chen JL, Lin YJ et al. ; Laparoscopic surgery for large left lateral liver tumors: safety and oncologic outcomes. *Surg Endosc.* 2018 Oct;32(10):4314–4320. doi: 10.1007/s00464-018-6287-9. [PubMed: 29959523]



**Figure 1.**  
Cutoff analysis

Comparison of baseline clinical and surgical characteristics of patients who underwent laparoscopic left lateral sectionectomy, stratified by tumor size.

Table 1:

	All N = 1910	Tumor size 39mm N = 1027	Tumor size 40- 69mm N = 528	Tumor size 70- 99mm N = 212	Tumor size 100mm N = 143	P-value (inequality between groups) <sup>‡</sup>
Median age (IQR), yrs	61 (50-71)	62 (53-71)	61 (49-72)	58 (45-68)	54 (41-69)	<0.001
Male sex, n (%)	1124 (58.8%)	658 (64.1%)	289 (54.7%)	115 (54.2%)	62 (43.4%)	<0.001
Year of surgery 2004-2012	414 (21.7%)	244 (23.8%)	97 (17.8%)	48 (22.6%)	28 (19.6%)	0.049
2013-2021	1496 (78.3%)	783 (76.2%)	434 (82.2%)	164 (77.4%)	115 (80.4%)	
Previous abdominal surgery, n/total (%)	555/1846 (30.1%)	317/988 (32.1%)	141/514 (27.4%)	55/205 (26.8%)	42/139 (30.2%)	0.205
Concomitant minor surgery, n (%)	70 (3.7%)	35 (3.4%)	22 (4.2%)	10 (4.7%)	3 (2.1%)	0.543
ASA score, n/total (%)	285/1909 (14.9%)	136/1027 (13.2%)	78/528 (14.8%)	47/212 (22.2%)	24/142 (16.9%)	0.017
1	1176/1909 (61.6%)	630/1027 (61.3%)	326/528 (61.7%)	126/212 (59.4%)	94/142 (66.2%)	
2	440/1909 (23.1%)	258/1027 (25.1%)	122/528 (23.1%)	37/212 (17.5%)	23/142 (16.2%)	
3	8/1909 (0.4%)	3/1027 (0.3%)	2/528 (0.4%)	2 (0.9%)	1/142 (0.7%)	
Malignant neoplasm, n (%)	1512 (79.2%)	922 (89.8%)	387 (73.3%)	124 (58.5%)	79 (55.2%)	<0.001
Cirrhosis, n/total (%)	602/1909 (31.5%)	388/1026 (37.8%)	142/528 (26.9%)	49/212 (23.1%)	23/143 (16.1%)	<0.001
Portal hypertension, n/total (%)	143/1900 (7.5%)	91/1021 (8.9%)	37/526 (7.0%)	14/211 (6.6%)	1/142 (0.7%)	0.001
Median tumor size, mm (IQR)	35 (23-58)	25 (18-30)	50 (41-57)	80 (70-86)	120 (101-131)	<0.001
Multiple tumors, n (%)	317 (16.6%)	177 (17.2%)	89 (16.9%)	35 (16.5%)	16 (11.2%)	0.335
Median Iwate difficulty score, (IQR)	5 (4-5)	4 (4-5)	5 (5-6)	5 (5-6)	5 (5-6)	<0.001
Median Iwate difficulty score <i>excluding</i> tumor size, (IQR)	4 (4-5)	4 (4-4)	4 (4-5)	4 (4-5)	4 (4-5)	<0.001
Iwate difficulty, n (%)	131 (6.9%)	130 (12.7%)	1 (0.2%)	0 (0.0%)	0 (0.0%)	<0.001
Low	1763 (92.3%)	891 (86.8%)	519 (98.3%)	210 (99.1%)	143 (100.0%)	
Intermediate	16 (0.8%)	6 (0.6%)	8 (1.5%)	2 (0.9%)	0 (0.0%)	
High	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Expert						

<sup>‡</sup>Kruskal-Wallis test for continuous variables and Fisher's exact test for categorical variables.

IQR, interquartile range, ASA physical status classification system.

**Table 2.**

Cutoff analysis for nine selected endpoints.

Tumor size (cm)	Open conversion RR (95% CI)	Operation time (mins) MD (95% CI)	Estimated blood loss (ml) MD (95% CI)	Blood transfusion RR (95% CI)	Pringle maneuver RR (95% CI)	Post-op length of stay MD (95% CI)	Post-op complications RR (95% CI)	Major complications RR (95% CI)	90-day mortality RR (95% CI)
>1.0 vs 1.0	0.9 (0.25 to 3.27)	7 (-11 to 26)	16 (-28 to 61)	4.58 (0.28 to 74.81)	0.96 (0.52 to 1.76)	0.6 (-0.3 to 1.6)	0.84 (0.43 to 1.64)	1.27 (0.25 to 6.57)	0.28 (0.05 to 1.55)
>2.0 vs 2.0	1.33 (0.7 to 2.54)	9 (1 to 17)	11 (-8 to 29)	2.1 (0.97 to 4.55)	1.77 (1.3 to 2.4)	0.2 (-0.2 to 0.6)	1.27 (0.91 to 1.78)	1.33 (0.65 to 2.71)	2.22 (0.4 to 12.23)
>3.0 vs 3.0	1.98 (1.14 to 3.42)	10 (3 to 16)	5 (-10 to 21)	1.84 (1.06 to 3.21)	1.68 (1.32 to 2.13)	0 (-0.3 to 0.4)	1.25 (0.96 to 1.64)	1.07 (0.61 to 1.85)	2.14 (0.65 to 7.33)
>4.0 vs 4.0	2.21 (1.33 to 3.67)	11 (4 to 18)	7 (-8 to 23)	2.51 (1.48 to 4.23)	1.88 (1.49 to 2.36)	-0.1 (-0.4 to 0.3)	1.2 (0.92 to 1.57)	1.42 (0.82 to 2.46)	1.52 (0.51 to 4.54)
>5.0 vs 5.0	2.26 (1.37 to 3.73)	16 (8 to 23)	15 (-2 to 31)	2.86 (1.71 to 4.77)	2.17 (1.71 to 2.75)	-0.2 (-0.6 to 0.2)	1.14 (0.86 to 1.52)	1.67 (0.96 to 2.91)	1.28 (0.41 to 4.02)
>6.0 vs 6.0	2.33 (1.39 to 3.91)	18 (10 to 27)	17 (-1 to 36)	2.92 (1.74 to 4.91)	2.13 (1.65 to 2.75)	-0.2 (-0.6 to 0.2)	1.03 (0.75 to 1.42)	1.83 (1.02 to 3.27)	1.94 (0.61 to 6.1)
>7.0 vs 7.0	2.46 (1.43 to 4.26)	24 (14 to 33)	30 (8 to 51)	3.09 (1.8 to 5.3)	2.11 (1.59 to 2.8)	0.1 (-0.4 to 0.5)	1.02 (0.71 to 1.46)	2.09 (1.13 to 3.87)	2 (0.58 to 6.86)
>8.0 vs 8.0	2.69 (1.49 to 4.86)	24 (13 to 35)	33 (8 to 57)	3.43 (1.93 to 6.09)	2.21 (1.61 to 3.05)	0 (-0.5 to 0.6)	1.05 (0.7 to 1.59)	2.57 (1.34 to 4.93)	1.92 (0.48 to 7.7)
>9.0 vs 9.0	2.44 (1.26 to 4.72)	26 (14 to 39)	43 (16 to 71)	4.28 (2.38 to 7.73)	2.33 (1.63 to 3.32)	0.2 (-0.5 to 0.8)	1.03 (0.65 to 1.65)	2.41 (1.17 to 4.96)	1.4 (0.25 to 7.71)
>10.0 vs 10.0	3.35 (1.63 to 6.89)	38 (23 to 53)	62 (25 to 98)	4.58 (2.33 to 8.99)	2.34 (1.5 to 3.64)	0.1 (-0.7 to 0.9)	0.74 (0.39 to 1.42)	2.61 (1.12 to 6.09)	2.36 (0.43 to 13.11)
>11.0 vs 11.0	2.81 (1.21 to 6.55)	42 (25 to 59)	56 (14 to 98)	4.15 (1.94 to 8.91)	1.65 (0.98 to 2.78)	0.2 (-0.7 to 1.1)	0.89 (0.45 to 1.79)	3.5 (1.49 to 8.22)	3.11 (0.56 to 17.33)
>12.0 vs 12.0	4.59 (1.93 to 10.89)	34 (13 to 55)	29 (-28 to 86)	3.93 (1.56 to 9.92)	1.31 (0.67 to 2.57)	0.1 (-1 to 1.2)	1.12 (0.51 to 2.46)	3.62 (1.32 to 9.93)	4.88 (0.87 to 26.8)
>13.0 vs 13.0	4.95 (1.94 to 12.63)	45 (21 to 69)	38 (-24 to 100)	5.22 (2.04 to 13.35)	1.82 (0.9 to 3.67)	0.4 (-0.9 to 1.6)	1.03 (0.42 to 2.57)	3.53 (1.14 to 10.97)	6.31 (1.12 to 35.65)
>14.0 vs 14.0	4.92 (1.55 to 15.68)	37 (7 to 68)	-22 (-107 to 63)	5.18 (1.62 to 16.53)	1 (0.36 to 2.83)	0.1 (-1.5 to 1.7)	1.06 (0.34 to 3.29)	4.05 (1.06 to 15.39)	10.43 (1.81 to 59.97)
>15.0 vs 15.0	5.15 (1.31 to 20.18)	44 (6 to 81)	-22 (-129 to 85)	2.99 (0.55 to 16.28)	1.26 (0.38 to 4.19)	0.1 (-1.9 to 2)	0.62 (0.12 to 3.36)	3.47 (0.63 to 18.96)	4.57 (0.26 to 80.46)

RR relative risk, CI confidence interval, MD median.

Effect sizes were computed by dichotomizing the tumor size at every 10mm-interval (for example, at the tumor size cutoff of 10cm, the effect size of RR 3.35 [95% CI 1.63–6.89] for the outcome of open conversion represents the risk ratio obtained when comparing the rate of open conversion among patients with tumor size >100mm versus patients with tumor size ≤100mm). Effect sizes were adjusted using inverse probability-weights from a logistic regression incorporating the following as covariates: age, gender, year of surgery, ASA status, previous abdominal surgery, concomitant minor surgery, cirrhosis, multifocality, difficult posterosuperior segment, malignant pathology, and all components of the Iwate score excluding tumor size.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**Table 3:** Comparison of perioperative outcomes of patients who underwent laparoscopic left lateral sectionectomy, stratified by tumor size

	All N = 1910	Tumor size 39mm N = 1027	Tumor size 40–69mm N = 528	Tumor size 70–99mm N = 212	Tumor size 100mm N = 143	Z-statistic & P-value for monotonic trend <sup>†</sup>
Open conversion, n (%)	63 (3.3%)	22 (2.1%)	18 (3.4%)	13 (6.1%)	10 (7.0%)	Z=3.90; P<0.001
Median operating time (IQR), min	160 (112–215)	155 (105–215)	157 (112–210)	180 (120–220)	180 (126–235)	Z=3.84; P<0.001
Median blood loss (IQR), ml	100 (50–200)	50 (30–153)	100 (50–200)	100 (50–250)	200 (50–300)	Z=6.50; P<0.001
Intraoperative blood transfusion, n (%)	60 (3.1%)	19 (1.9%)	16 (3.0%)	11 (5.2%)	14 (9.8%)	Z=5.15; P<0.001
Pringle maneuver applied, n (%)	365/1868 (19.5%)	157/1011 (15.5%)	99/514 (19.3%)	60 (28.8%)	48/135 (35.6%)	Z=6.48; P<0.001
Median postoperative stay (IQR), days	5 (3–6)	5 (4–6)	5 (3–6)	5 (3–6)	5 (3–6)	Z=0.84; P=0.399
Overall morbidity, n (%)	255/1909 (13.4%)	125/1026 (12.2%)	80/528 (15.2%)	32/212 (15.1%)	18/143 (12.6%)	Z=0.97; P=0.330
Major morbidity (Clavien-Dindo grade>2)	52/1909 (2.7%)	24/1026 (2.3%)	12/528 (2.3%)	8/212 (3.8%)	8/143 (5.6%)	Z=2.17; P=0.030
30-day readmission, n (%)	44/1901 (2.3%)	17/1021 (1.7%)	15/527 (2.8%)	7/211 (3.3%)	5/142 (3.5%)	Z=1.99; P=0.047
30-day mortality, n (%)	7 (0.4%)	2 (0.2%)	3 (0.6%)	1 (0.5%)	1 (0.7%)	Z=1.19; P=0.233
90-day mortality, n (%)	12 (0.6%)	4 (0.4%)	4 (0.8%)	3 (1.4%)	1 (0.7%)	Z=1.34; P=0.180
Close margins, n (%)	110/1902 (5.8%)	54/1020 (5.3%)	44/528 (8.3%)	6/212 (2.8%)	6/142 (4.2%)	Z=-0.57; P=0.571

<sup>†</sup>Two-sided Cochran-Armitage or Jonckheere-Terpstra tests were used to evaluate the presence of a monotonic increasing or decreasing trend over the four tumor size categories, which was treated as an ordinal variable (i.e., Group 1: <40mm, Group 2: 40–69mm, Group 3: 70–99mm, Group 4: 100mm).

IQR, interquartile range